

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Raily Aesthetic Medicine International Holdings Limited**

**瑞麗醫美國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2135)**

### **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024**

Reference is made to the annual report for the year ended 31 December 2024 (the “**2024 Annual Report**”) of Raily Aesthetic Medicine International Holdings Limited (the “**Company**”) published on 24 April 2025. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those used in the 2024 Annual Report. This supplemental announcement should be read in conjunction with the 2024 Annual Report.

#### **Use of Proceeds**

In addition to the information provided in the section headed “USE OF PROCEEDS” in the 2024 Annual Report, the Board would like to clarify that:

- (i) as at the date of this supplemental announcement, HK\$8.6 million out of the net proceeds from the Listing for organic growth remains unutilized, while other proceeds have been fully utilized. The Company proposed to use the unutilised proceeds of HK\$8.6 million by 31 December 2025, according to the intentions previously disclosed by the Company. The delay in utilizing the proceeds is primarily due to that no suitable aesthetic medical institution was identified in Shanghai City during the period of COVID-19 from 2021 to 2024. Originally, it is believed that establishing an aesthetic medical hospital in Shanghai City can boost client’s confidence, enhance brand influence and further reinforce the Company’s corporate profile, which in turn allows the Company to further attract clients and expand its business in China. However, COVID-19 during the aforesaid period has impacted the aesthetical industry in Shanghai City resulting in limited business opportunity and growth. As such, the Company determines to postpone the utilization of the remaining proceeds to the end of 31 December 2025; and
- (ii) as at the date of this supplemental announcement, HK\$7.6 million out of the net proceeds from the Rights Issue for registration filing of aesthetic medical equipment products with the NMPA (including clinical trials which are integral to the registration process) remains unutilized, while other proceeds have been fully utilized. The Company proposed to use

the unutilized proceeds of HK\$7.6 million by 31 March 2026, according to the intentions previously disclosed by the Company. The delay in utilizing the proceeds is primarily due to that the Company is still in the process of preparing for registration of aesthetic medical equipment products.

The Company will keep its shareholders and investors informed of the progress of the utilization of the proceeds as abovementioned and issue further announcement(s) as and when appropriate or as required under the Listing Rules.

### Share Option Scheme

In addition to the information provided in the 2024 Annual Report, the Board would like to provide the following additional information on the share option scheme of the Company which is set out in the section headed “SHARE OPTION SCHEME” in the 2024 Annual Report:

| <b>Name or category of grantees</b> | <b>Date of grant of share options</b> | <b>Closing price of the shares immediately before the date on which the options were granted (HK\$)</b> | <b>Fair value of options at the date of grant (HK\$)</b> |
|-------------------------------------|---------------------------------------|---|--|
| <b>Directors</b>                    |                                       |   |  |
| Song Jianliang                      | 23/08/2021                            | 0.485   | 0.080  |
| Wang Ying                           | 23/08/2021                            | 0.485   | 0.080  |
| <b>Other employees</b>              |                                       |   |  |
| In aggregate                        | 23/08/2021                            | 0.485   | 0.080  |
|                                     | 29/08/2022                            | 0.167   | 0.076  |
|                                     | 29/08/2022                            | 0.167   | 0.076  |
|                                     | 29/08/2022                            | 0.167   | 0.076  |
|                                     | 29/08/2022                            | 0.167   | 0.076  |
|                                     | 26/01/2024                            | 0.112   | 0.079  |
|                                     | 23/02/2024                            | 0.122   | 0.082  |
|                                     | 23/02/2024                            | 0.122   | 0.082  |
| <b>Service Providers</b>            |                                       |   |  |
| In aggregate                        | 23/08/2021                            | 0.485   | 0.080  |
|                                     | 29/08/2022                            | 0.167   | 0.076  |
|                                     | 29/08/2022                            | 0.167   | 0.076  |
|                                     | 29/08/2022                            | 0.167   | 0.076  |
|                                     | 29/08/2022                            | 0.167   | 0.076  |

The supplemental information in this announcement does not affect any other information contained in the 2024 Annual Report. Save for the above, all other information in the 2024 Annual Report remains unchanged.

By Order of the Board  
**Raily Aesthetic Medicine International Holdings Limited**  
**Mr. Fu Haishu**  
*Chairman and Executive Director*

Hangzhou, the PRC, 10 October 2025

*As at the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Song Jianliang and Mr. Wang Ying as Executive Directors; and Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng as Independent Non-executive Directors.*